HRP20130028T1 - Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina - Google Patents
Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina Download PDFInfo
- Publication number
- HRP20130028T1 HRP20130028T1 HRP20130028TT HRP20130028T HRP20130028T1 HR P20130028 T1 HRP20130028 T1 HR P20130028T1 HR P20130028T T HRP20130028T T HR P20130028TT HR P20130028 T HRP20130028 T HR P20130028T HR P20130028 T1 HRP20130028 T1 HR P20130028T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- host organism
- vkd
- recombinant
- nucleic acid
- Prior art date
Links
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 title claims 11
- 230000014509 gene expression Effects 0.000 title claims 8
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 title 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 title 1
- 230000004186 co-expression Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 101000621945 Homo sapiens Vitamin K epoxide reductase complex subunit 1 Proteins 0.000 claims 9
- 102100023485 Vitamin K epoxide reductase complex subunit 1 Human genes 0.000 claims 9
- 230000028327 secretion Effects 0.000 claims 8
- 239000003114 blood coagulation factor Substances 0.000 claims 6
- 238000004113 cell culture Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 claims 5
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims 5
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 108010014173 Factor X Proteins 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical group [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229940012426 factor x Drugs 0.000 claims 2
- 229960000027 human factor ix Drugs 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (18)
1. Organizam domaćina, naznačen time, da sadrži jednu rekombinantnu nukleinsku kiselinu, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1) i jednu rekombinantnu nukleinsku kiselinu, koja kodira za vitamin K-ovisan protein (VKD), pri čemu su i rekombinantna VKORC1 kao i rekombinantni VKD-protein eksprimirani u spomenutom organizmu domaćina, te je pritom količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećana u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira rVKORC1.
2. Organizam domaćina prema zahtjevu 1, naznačen time, da je eksprimirana ili nukleinska kiselina koja kodira za rekombinantni VKORC1 ili nukleinska kiselina koja kodira za rekombinantni VKD-protein ili su obje eksprimirane, i to putem načina ekspresije odabranog iz skupine koju čine inducirana, tranzijentna i permanentna ekspresija.
3. Organizam domaćina prema zahtjevu 1 ili 2, naznačen time, da organizam domaćina je stanica sisavca.
4. Organizam domaćina prema zahtjevu 3, naznačen time, da je stanica sisavca jedna stanica dobivena iz stanične linije sisavaca odabrane iz skupine koju čine CHO-stanice i HEK293-stanice.
5. Organizam domaćina prema bilo kojem od zahtjeva 1 do 4, naznačen time, da rekombinantni VKD-protein je faktor zgrušavanja krvi.
6. Organizam domaćina prema bilo zahtjevu 5, naznačen time, da je faktor zgrušavanja krvi odabran iz skupine koju čine faktor II, faktor VII, faktor IX i faktor X.
7. Organizam domaćina prema bilo zahtjevu 6, naznačen time, da faktor zgrušavanja krvi je humani faktor IX.
8. Sustav stanične kulture, naznačen time, da obuhvaća stanice koje sadrže jednu rekombinantnu nukleinsku kiselinu, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1) i jednu rekombinantnu nukleinsku kiselinu, koja kodira za vitamin K-ovisan protein (VKD), pri čemu su i rekombinantna VKORC1 kao i rekombinantni VKD-protein eksprimirani u spomenutim stanicama, te se pritom količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira rVKORC1.
9. Sustav stanične kulture prema zahtjevu 8, naznačen time, da kultivirane stanice su stanice sisavca.
10. Sustav stanične kulture prema zahtjevu 9, naznačen time, da su stanice sisavca odabrane iz skupine koju čine CHO-stanice i HEK293-stanice.
11. Sustav stanične kulture prema zahtjevu 8 do 10, naznačen time, da rekombinantni VKD-protein je faktor zgrušavanja krvi.
12. Sustav stanične kulture prema zahtjevu 11, naznačen time, da je faktor zgrušavanja krvi odabran iz skupine koju čine faktor II, faktor VII, faktor IX i faktor X.
13. Sustav stanične kulture prema zahtjevu 12, naznačen time, da faktor zgrušavanja krvi je humani faktor IX.
14. Postupak povećanja količine sekrecije rekombinantnog vitamin K-ovisnog proteina (VKD) u organizmu domaćina, naznačen time, da obuhvaća sljedeće korake:
dobavljanje organizma domaćina;
umetanje rekombinantne nukleinske kiseline, koja kodira za VKD-protein, u organizam domaćina iz koraka (a);
umetanje rekombinantne nukleinske kiseline, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1), u organizam domaćina iz koraka (a); i
eksprimiranje rekombinantnih nukleinskih kiselina iz koraka (b) i (c);
pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira rVKORC1.
15. Postupak povećanja količine sekrecije rekombinantnog vitamin K-ovisnog proteina (VKD) u organizmu domaćina, naznačen time, da obuhvaća sljedeće korake:
(a) dobavljanje organizma domaćina s rekombinantnom nukleinskom kiselinom, koja kodira za VKD-protein, integriranom u njegovom genomu;
(b) umetanje rekombinantne nukleinske kiseline, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1), u organizam domaćina iz koraka (a); i
(c) eksprimiranje nukleinskih kiselina iz koraka (a) i (b);
pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira rVKORC1.
16. Postupak prema zahtjevu 15, naznačen time, da se stabilno eksprimira rekombinantna nukleinska kiselina, koja kodira za VKD-protein.
17. Postupak povećanja količine sekrecije rekombinantnog vitamin K-ovisnog proteina (VKD) u organizmu domaćina, naznačen time, da obuhvaća sljedeće korake:
(a) dobavljanje organizma domaćina s rekombinantnom nukleinskom kiselinom, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1), integriranom u njegovom genomu;
(b) umetanje rekombinantne nukleinske kiseline, koja kodira za VKD-protein, u organizam domaćina iz koraka (a);
(c ksprimiranje nukleinskih kiselina iz koraka (a) i (b);
pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domaćina, koji ne ko-eksprimira rVKORC1.
18. Postupak prema zahtjevu 17, naznačen time, da se stabilno eksprimira rekombinantna nukleinska kiselina, koja kodira za VKORC1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65704105P | 2005-02-28 | 2005-02-28 | |
| PCT/EP2006/000734 WO2006089613A1 (en) | 2005-02-28 | 2006-01-27 | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130028T1 true HRP20130028T1 (hr) | 2013-02-28 |
Family
ID=36130202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130028TT HRP20130028T1 (hr) | 2005-02-28 | 2013-01-15 | Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9617523B2 (hr) |
| EP (2) | EP1853700B1 (hr) |
| JP (3) | JP2008531026A (hr) |
| KR (2) | KR20130025952A (hr) |
| CN (2) | CN101124320A (hr) |
| AU (1) | AU2006218216B2 (hr) |
| BR (1) | BRPI0607751A8 (hr) |
| CA (1) | CA2599284A1 (hr) |
| DK (1) | DK1853700T3 (hr) |
| ES (1) | ES2397530T3 (hr) |
| HK (1) | HK1113498A1 (hr) |
| HR (1) | HRP20130028T1 (hr) |
| IL (1) | IL184696A (hr) |
| MX (2) | MX349285B (hr) |
| PL (1) | PL1853700T3 (hr) |
| PT (1) | PT1853700E (hr) |
| SI (1) | SI1853700T1 (hr) |
| WO (1) | WO2006089613A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2380985B1 (en) * | 2003-09-23 | 2014-01-01 | University of North Carolina at Chapel Hill | Cells expressing vitamin K epoxide reductase and use thereof |
| DE602004026897D1 (de) | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| PL1853700T3 (pl) | 2005-02-28 | 2013-05-31 | Baxalta Inc | Koekspresja przez rekombinowanie podjednostki 1 reduktazy epoksydu witaminy K w celu poprawy ekspresji białka zależnego od witaminy K |
| AU2005329450A1 (en) * | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
| US8647868B2 (en) * | 2005-12-02 | 2014-02-11 | Wake Forest University Health Sciences | Compositions and methods for increasing production of recombinant gamma-carboxylated proteins |
| US20080045453A1 (en) * | 2005-12-21 | 2008-02-21 | Drohan William N | Method of producing biologically active vitamin K dependent proteins by recombinant methods |
| AU2009239641B2 (en) | 2008-04-24 | 2013-11-07 | Cantab Biopharmaceuticals Patents Limited | Factor IX conjugates with extended half-lives |
| CN102471794B (zh) * | 2009-07-10 | 2014-10-29 | Csl有限公司 | 提高维生素k依赖性蛋白质的表达产量的方法 |
| EP2655607A4 (en) * | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS |
| JP2012139232A (ja) * | 2012-03-15 | 2012-07-26 | Univ Of North Carolina At Chapel Hill | 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物 |
| RU2535871C1 (ru) * | 2013-07-10 | 2014-12-20 | Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") | Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом |
| JP2014221048A (ja) * | 2014-06-16 | 2014-11-27 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物 |
| CN104293737B (zh) * | 2014-09-16 | 2017-06-13 | 太原博奥特生物技术有限公司 | 一种包含表达功能性重组人凝血因子ⅶ载体的宿主细胞及其高水平表达方法 |
| DK3383894T3 (da) | 2015-12-02 | 2020-06-02 | CSL Behring Lengnau AG | Forbedrede medier til eksprimering af rekombinante vitamin k-afhængige proteiner |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8822584D0 (en) | 1988-09-27 | 1988-11-02 | Abco Technology Ltd | Steam boiler system |
| WO1991001372A1 (en) | 1989-07-17 | 1991-02-07 | New England Medical Center Hospitals, Inc. | VITAMIN K-DEPENDENT η-CARBOXYLASE |
| WO1992001795A1 (en) | 1990-07-23 | 1992-02-06 | Zymogenetics, Inc. | Gamma-carboxylase and methods of use |
| US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
| WO2002095010A2 (en) | 2001-03-21 | 2002-11-28 | Human Genome Sciences, Inc. | Human secreted proteins |
| EP1097202A2 (en) | 1998-07-10 | 2001-05-09 | Incyte Pharmaceuticals, Inc. | Human transport protein homologs |
| IL154879A0 (en) | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Factor vii glycoforms |
| EP2380985B1 (en) * | 2003-09-23 | 2014-01-01 | University of North Carolina at Chapel Hill | Cells expressing vitamin K epoxide reductase and use thereof |
| DE602004026897D1 (de) * | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| EP1831363A1 (en) * | 2004-12-21 | 2007-09-12 | Novo Nordisk Health Care AG | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems |
| PL1853700T3 (pl) | 2005-02-28 | 2013-05-31 | Baxalta Inc | Koekspresja przez rekombinowanie podjednostki 1 reduktazy epoksydu witaminy K w celu poprawy ekspresji białka zależnego od witaminy K |
| AU2005329450A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
-
2006
- 2006-01-27 PL PL06706455T patent/PL1853700T3/pl unknown
- 2006-01-27 ES ES06706455T patent/ES2397530T3/es active Active
- 2006-01-27 CA CA002599284A patent/CA2599284A1/en not_active Abandoned
- 2006-01-27 EP EP06706455A patent/EP1853700B1/en not_active Revoked
- 2006-01-27 SI SI200631503T patent/SI1853700T1/sl unknown
- 2006-01-27 KR KR1020137002337A patent/KR20130025952A/ko not_active Application Discontinuation
- 2006-01-27 JP JP2007557348A patent/JP2008531026A/ja not_active Ceased
- 2006-01-27 PT PT67064550T patent/PT1853700E/pt unknown
- 2006-01-27 CN CNA2006800047124A patent/CN101124320A/zh active Pending
- 2006-01-27 CN CN201310245632XA patent/CN103396998A/zh active Pending
- 2006-01-27 KR KR1020077022018A patent/KR101310532B1/ko active IP Right Grant
- 2006-01-27 DK DK06706455.0T patent/DK1853700T3/da active
- 2006-01-27 WO PCT/EP2006/000734 patent/WO2006089613A1/en active Application Filing
- 2006-01-27 MX MX2012009048A patent/MX349285B/es unknown
- 2006-01-27 US US11/342,299 patent/US9617523B2/en not_active Expired - Fee Related
- 2006-01-27 MX MX2007010489A patent/MX2007010489A/es active IP Right Grant
- 2006-01-27 AU AU2006218216A patent/AU2006218216B2/en not_active Ceased
- 2006-01-27 BR BRPI0607751A patent/BRPI0607751A8/pt not_active Application Discontinuation
- 2006-01-27 EP EP10010933.9A patent/EP2295547B1/en not_active Revoked
-
2007
- 2007-07-18 IL IL184696A patent/IL184696A/en not_active IP Right Cessation
-
2008
- 2008-04-01 HK HK08103591.9A patent/HK1113498A1/xx not_active IP Right Cessation
-
2011
- 2011-04-28 JP JP2011102480A patent/JP2011142923A/ja active Pending
-
2012
- 2012-12-21 JP JP2012279460A patent/JP5339391B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-15 HR HRP20130028TT patent/HRP20130028T1/hr unknown
-
2017
- 2017-01-18 US US15/409,032 patent/US20170226487A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070110106A (ko) | 2007-11-15 |
| JP2008531026A (ja) | 2008-08-14 |
| JP5339391B2 (ja) | 2013-11-13 |
| CA2599284A1 (en) | 2006-08-31 |
| EP1853700B1 (en) | 2012-10-24 |
| CN103396998A (zh) | 2013-11-20 |
| US20060194284A1 (en) | 2006-08-31 |
| CN101124320A (zh) | 2008-02-13 |
| SI1853700T1 (sl) | 2013-02-28 |
| BRPI0607751A2 (pt) | 2010-03-16 |
| IL184696A0 (en) | 2007-12-03 |
| EP1853700A1 (en) | 2007-11-14 |
| PT1853700E (pt) | 2013-01-14 |
| IL184696A (en) | 2013-09-30 |
| BRPI0607751A8 (pt) | 2015-10-27 |
| HK1113498A1 (en) | 2008-10-03 |
| EP2295547B1 (en) | 2017-09-20 |
| JP2011142923A (ja) | 2011-07-28 |
| MX349285B (es) | 2017-07-20 |
| ES2397530T3 (es) | 2013-03-07 |
| PL1853700T3 (pl) | 2013-05-31 |
| JP2013063089A (ja) | 2013-04-11 |
| WO2006089613A1 (en) | 2006-08-31 |
| KR101310532B1 (ko) | 2013-09-23 |
| MX2007010489A (es) | 2007-11-08 |
| DK1853700T3 (da) | 2013-01-07 |
| US20170226487A1 (en) | 2017-08-10 |
| KR20130025952A (ko) | 2013-03-12 |
| EP2295547A1 (en) | 2011-03-16 |
| US9617523B2 (en) | 2017-04-11 |
| AU2006218216B2 (en) | 2011-01-20 |
| AU2006218216A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130028T1 (hr) | Rekombinantna ko-ekspresija podjedinice reduktaze vitamin k epoksida u svrhu poboljšanja ekspresije vitamin k-ovisnog proteina | |
| BR112012015255A2 (pt) | "anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante" | |
| DE60324430D1 (de) | Methode um rekombinante proteine in cho zellen zu exprimieren | |
| WO2009023525A3 (en) | Methods of modulating mesenchymal stem cell differentiation | |
| BR112012015576A2 (pt) | "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso" | |
| UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
| EP2428223A3 (en) | Use of human cells of myeloid leukaemia origin for expression of antibodies | |
| BR112012013782A2 (pt) | "antagonistas de pcsk9" | |
| MX2007003906A (es) | Metodos y composiciones para mejorar la produccion de proteinas recombinantes. | |
| NZ712943A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| BRPI0820177B8 (pt) | métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas | |
| BRPI0819649A2 (pt) | método, organismo geneticamente modificado, e, célula de levedura recinbinante | |
| AR079707A1 (es) | Celula aislada de ovario de hamster chino util para la produccion de anticuerpos terapeuticos | |
| Li et al. | Hepatitis C viral replication complex | |
| WO2010086743A3 (en) | Codon-optimised hepatitis b virus core antigen | |
| NZ609567A (en) | Markers of endothelial progenitor cells and uses thereof | |
| UA108836C2 (uk) | Спосіб одержання секретованого білка в підживлюваній культурі клітин яєчників китайського хом'ячка | |
| Li et al. | Applications of replicating-competent reporter-expressing viruses in diagnostic and molecular virology | |
| Riedel et al. | Atypical porcine pestiviruses: Relationships and conserved structural features | |
| Xie et al. | Uterine micro-environment and estrogen-dependent regulation of osteopontin expression in mouse blastocyst | |
| NZ586037A (en) | Sm-protein based secretion engineering | |
| EP2600894A4 (en) | MODIFIED HEPATITIS C VIRUS PROTEINS | |
| CN103710368B (zh) | 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 | |
| El-Kehdy et al. | Inflammation differentially modulates the biological features of adult derived human liver stem/progenitor cells | |
| Zhang et al. | Paraoxonase-1 facilitates PRRSV replication by interacting with viral nonstructural protein-9 and inhibiting type I interferon pathway |